Contribution of Nanotechnologies to Vaccine Development and Drug Delivery against Respiratory Viruses
According to the Center for Disease Control and Prevention (CDC), the coronavirus disease 2019, a respiratory viral illness linked to significant morbidity, mortality, production loss, and severe economic depression, was the third-largest cause of death in 2020. Respiratory viruses such as influenza...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2021/6741290 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849309292749914112 |
|---|---|
| author | Mahdi Ftouh Nesrine Kalboussi Nabil Abid Souad Sfar Nathalie Mignet Badr Bahloul |
| author_facet | Mahdi Ftouh Nesrine Kalboussi Nabil Abid Souad Sfar Nathalie Mignet Badr Bahloul |
| author_sort | Mahdi Ftouh |
| collection | DOAJ |
| description | According to the Center for Disease Control and Prevention (CDC), the coronavirus disease 2019, a respiratory viral illness linked to significant morbidity, mortality, production loss, and severe economic depression, was the third-largest cause of death in 2020. Respiratory viruses such as influenza, respiratory syncytial virus, SARS-CoV-2, and adenovirus, are among the most common causes of respiratory illness in humans, spreading as pandemics or epidemics throughout all continents. Nanotechnologies are particles in the nanometer range made from various compositions. They can be lipid-based, polymer-based, protein-based, or inorganic in nature, but they are all bioinspired and virus-like. In this review, we aimed to present a short review of the different nanoparticles currently studied, in particular those which led to publications in the field of respiratory viruses. We evaluated those which could be beneficial for respiratory disease-based viruses; those which already have contributed, such as lipid nanoparticles in the context of COVID-19; and those which will contribute in the future either as vaccines or antiviral drug delivery systems. We present a short assessment based on a critical selection of evidence indicating nanotechnology’s promise in the prevention and treatment of respiratory infections. |
| format | Article |
| id | doaj-art-18de53fd7fc94969a3149e1c5c1668a2 |
| institution | Kabale University |
| issn | 1687-4765 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-18de53fd7fc94969a3149e1c5c1668a22025-08-20T03:54:12ZengWileyPPAR Research1687-47652021-01-01202110.1155/2021/6741290Contribution of Nanotechnologies to Vaccine Development and Drug Delivery against Respiratory VirusesMahdi Ftouh0Nesrine Kalboussi1Nabil Abid2Souad Sfar3Nathalie Mignet4Badr Bahloul5Drug Development Laboratory LR12ES09Drug Development Laboratory LR12ES09Department of BiotechnologyDrug Development Laboratory LR12ES09University of ParisDrug Development Laboratory LR12ES09According to the Center for Disease Control and Prevention (CDC), the coronavirus disease 2019, a respiratory viral illness linked to significant morbidity, mortality, production loss, and severe economic depression, was the third-largest cause of death in 2020. Respiratory viruses such as influenza, respiratory syncytial virus, SARS-CoV-2, and adenovirus, are among the most common causes of respiratory illness in humans, spreading as pandemics or epidemics throughout all continents. Nanotechnologies are particles in the nanometer range made from various compositions. They can be lipid-based, polymer-based, protein-based, or inorganic in nature, but they are all bioinspired and virus-like. In this review, we aimed to present a short review of the different nanoparticles currently studied, in particular those which led to publications in the field of respiratory viruses. We evaluated those which could be beneficial for respiratory disease-based viruses; those which already have contributed, such as lipid nanoparticles in the context of COVID-19; and those which will contribute in the future either as vaccines or antiviral drug delivery systems. We present a short assessment based on a critical selection of evidence indicating nanotechnology’s promise in the prevention and treatment of respiratory infections.http://dx.doi.org/10.1155/2021/6741290 |
| spellingShingle | Mahdi Ftouh Nesrine Kalboussi Nabil Abid Souad Sfar Nathalie Mignet Badr Bahloul Contribution of Nanotechnologies to Vaccine Development and Drug Delivery against Respiratory Viruses PPAR Research |
| title | Contribution of Nanotechnologies to Vaccine Development and Drug Delivery against Respiratory Viruses |
| title_full | Contribution of Nanotechnologies to Vaccine Development and Drug Delivery against Respiratory Viruses |
| title_fullStr | Contribution of Nanotechnologies to Vaccine Development and Drug Delivery against Respiratory Viruses |
| title_full_unstemmed | Contribution of Nanotechnologies to Vaccine Development and Drug Delivery against Respiratory Viruses |
| title_short | Contribution of Nanotechnologies to Vaccine Development and Drug Delivery against Respiratory Viruses |
| title_sort | contribution of nanotechnologies to vaccine development and drug delivery against respiratory viruses |
| url | http://dx.doi.org/10.1155/2021/6741290 |
| work_keys_str_mv | AT mahdiftouh contributionofnanotechnologiestovaccinedevelopmentanddrugdeliveryagainstrespiratoryviruses AT nesrinekalboussi contributionofnanotechnologiestovaccinedevelopmentanddrugdeliveryagainstrespiratoryviruses AT nabilabid contributionofnanotechnologiestovaccinedevelopmentanddrugdeliveryagainstrespiratoryviruses AT souadsfar contributionofnanotechnologiestovaccinedevelopmentanddrugdeliveryagainstrespiratoryviruses AT nathaliemignet contributionofnanotechnologiestovaccinedevelopmentanddrugdeliveryagainstrespiratoryviruses AT badrbahloul contributionofnanotechnologiestovaccinedevelopmentanddrugdeliveryagainstrespiratoryviruses |